United States Adalimumab Biosimilar Market Size, Share, Growth, and Industry Analysis, By Type (Fully Human Monoclonal Antibodies, Recombinant Antibodies, Pegylated Antibodies), By Application (Rheumatoid Arthritis, Psoriasis, Inflammatory Bowel Disease), Regional Insights and Forecast to 2034

Table of Contents

1. Executive Summary
   1. Introduction
2. Market Introduction
   1. Market Definition
   2. Scope of the Study
   3. Market Structure
3. Research Methodology
   1. Primary Research
   2. Research Methodology
   3. Assumptions & Exclusions
   4. Secondary Data Sources
4. Market Factor Analysis
   1. Value Chain Analysis: United States Adalimumab Biosimilar Market
   2. Porters Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitution
      4. Threat of New Entrants
      5. Competitive Rivalry
5. Market Dynamics
   1. Drivers
   2. Restraints
   3. Opportunities
6. Recent Trends Analysis
7. Impact of COVID-19 on United States Adalimumab Biosimilar Market
   1. Pre and Post Covid -19 Market Scenario Analysis
   2. Market Recovery Timeline and Challenge
   3. Measures Taken by Top Players
8. Regulatory Landscape
9. United States Adalimumab Biosimilar Market, By Type
   1. Introduction
      1. Market Size and Forecast, By Type
   2. Fully Human Monoclonal Antibodies
      1. Market Size and Forecast, By Region
   3. Recombinant Antibodies
      1. Market Size and Forecast, By Region
   4. Pegylated Antibodies
      1. Market Size and Forecast, By Region
10. United States Adalimumab Biosimilar Market, By Application
    1. Introduction
       1. Market Size and Forecast, By Application
    2. Rheumatoid Arthritis
       1. Market Size and Forecast, By Region
    3. Psoriasis
       1. Market Size and Forecast, By Region
    4. Inflammatory Bowel Disease
       1. Market Size and Forecast, By Region
11. Regional Overview
    1. Introduction
       1. Market Size and Forecast
    2. U.S.
       1. Market Size and Forecast
          1. By Type
             1. Fully Human Monoclonal Antibodies
             2. Recombinant Antibodies
             3. Pegylated Antibodies
          2. By Application
             1. Rheumatoid Arthritis
             2. Psoriasis
             3. Inflammatory Bowel Disease
    3. Canada
       1. Market Size and Forecast
          1. By Type
             1. Fully Human Monoclonal Antibodies
             2. Recombinant Antibodies
             3. Pegylated Antibodies
          2. By Application
             1. Rheumatoid Arthritis
             2. Psoriasis
             3. Inflammatory Bowel Disease
12. Competitive Landscape, 2025
    1. Introduction
    2. United States Adalimumab Biosimilar Market Share Analysis, 2025 (%)
       1. Market Share Analysis, 2025
       2. Competition Ranking, 2025
       3. Key Developments & Growth Strategies
          1. Merger & Acquisition
          2. Product Launch
          3. Expansion
       4. Consolidated SWOT Analysis of Key Players
13. Company Profile
    1. Amgen Inc.
       1. Business Overview
       2. Financial Data
       3. Key Product domains
       4. Recent Developments
    2. Pfizer Inc.
    3. Samsung Bioepis
    4. Sandoz International GmbH
    5. Viatris Inc.
    6. Fresenius Kabi
    7. Coherus BioSciences
    8. Celltrion Inc.
    9. Boehringer Ingelheim
    10. Teva Pharmaceutical Industries
    11. Organon & Co.
    12. Biocon Biologics
    13. AbbVie Inc.
    14. Lupin Limited
    15. Dr. Reddy’s Laboratories